Umeh CA, Maoz H, Obi J, Dakoria R, Patel S, Maity G, Barve P. Remdesivir, dexamethasone and angiotensin-converting enzyme inhibitors use and mortality outcomes in COVID-19 patients with concomitant troponin elevation. World J Cardiol 2023; 15(9): 427-438 [PMID: 37900264 DOI: 10.4330/wjc.v15.i9.427]
Corresponding Author of This Article
Heather Maoz, MD, Doctor, Internal Medicine, Hemet Global Medical Center, 1117 E. Devonshire Ave., Hemet, CA 92543, United States. heathermaoz@gmail.com
Research Domain of This Article
Cardiac & Cardiovascular Systems
Article-Type of This Article
Retrospective Study
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Cardiol. Sep 26, 2023; 15(9): 427-438 Published online Sep 26, 2023. doi: 10.4330/wjc.v15.i9.427
Table 1 Descriptive statistics of continuous variables
n
Minimum
Maximum
Mean
SD
Length of stay
1788
1
117
11.77
11.73
Age
1788
20
110
66.36
16.36
Body mass index
1741
14.14
83.12
30.07
8.69
C-reactive protein
1575
0.05
54.38
14.60
9.57
Lactate dehydrogenase
1384
55
8180
487.45
525.15
Ferritin
1240
5.1
47560.8
1038.56
2187.49
Troponin
1788
0.01
32.78
0.49
2.41
Creatine phosphokinase
979
10
88961
755.30
4495.43
Platelet
1786
37
1176
328.47
138.68
White blood cell count
1787
2.4
80.7
16.12
9.05
Potassium
1513
2.70
8.50
4.82
0.84
Total bilirubin
1780
0.2
27.8
1.01
1.16
Table 2 Descriptive analysis of categorical variable
Frequency
Percent
Gender
Female
749
41.9%
Male
1039
58.1%
Race
Asian
109
6.1%
Black
81
4.5%
White
1152
64.4%
Others
446
24.9%
Expired
No
1254
70.1%
Yes
534
29.9%
Ventilator use
No
1352
75.6%
Yes
436
24.4%
Intensive care unit
No
1328
74.3%
Yes
460
25.7%
Remdesivir
No
853
49.1%
Yes
883
50.9%
Dexamethasone
No
568
31.8%
Yes
1220
68.2%
Angiotensin converting enzyme inhibitor
No
1441
80.6%
Yes
347
19.4%
Diabetes mellitus
No
1444
80.8%
Yes
344
19.2%
Hypertension
No
1032
57.7%
Yes
756
42.3%
Chronic kidney disease
No
1355
76.0%
Yes
427
24.0%
Acute kidney injury
No
1588
88.8%
Yes
200
11.2%
Congestive heart failure
No
1451
81.2%
Yes
337
18.8%
Chronic obstructive pulmonary disease
No
1678
93.8%
Yes
110
6.2%
Bradycardia
No
823
46.0%
Yes
965
54.0%
Troponin elevation
No
1583
88.5%
Yes
205
11.5%
Table 3 Bivariate analysis of the relationship between continuous variables and troponin elevation
Troponin elevation
n
Mean
SD
P value
Length of stay
0
1583
11.46
11.44
0.007
1
205
14.16
13.52
Age
0
1583
66.14
16.49
0.08
1
205
68.13
15.29
Body mass index
0
1540
30.11
8.62
0.64
1
201
29.80
9.20
Oxygen on admission
0
1415
94.47
6.27
0.27
1
187
94.20
6.69
C-reactive protein
0
1393
14.23
9.50
< 0.001
1
182
17.47
9.70
Lactate dehydrogenase
0
1236
447.71
363.69
< 0.001
1
148
819.34
1165.85
Ferritin
0
1099
956.44
1859.08
0.03
1
141
1678.58
3844.02
Creatine phosphokinase
0
863
586.10
4245.13
0.01
1
116
2014.03
5913.58
Platelet
0
1582
331.24
138.55
0.02
1
204
307.00
138.15
WBC
0
1583
15.66
8.97
< 0.001
1
204
19.76
8.88
Potassium
0
1341
4.78
0.83
< 0.001
1
172
5.07
0.92
Total bilirubin
0
1577
0.95
0.83
0.004
1
203
1.46
2.48
Table 4 Bivariate analysis of the relationship between categorical variables and troponin elevation
Variable
Troponin elevation
P value
No
Yes
Gender
Male
918 (88.4%)
121 (11.6%)
0.78
Female
665 (88.8%)
84 (11.2%)
Race
Asia
96 (88.1%)
13 (11.9%)
0.38
Black
72 (88.9%)
9 (11.1%)
White
1030 (89.4%)
122 (10.6%)
Others
385 (86.3%)
61 (13.7%)
Expired
Yes
415 (77.7%)
119 (22.3%)
< 0.001
No
1168 (93.1%)
86 (6.9%)
Ventilator
Yes
334 (76.6%)
102 (23.4%)
< 0.001
No
1249 (92.4%)
103 (7.5%)
Intensive care unit
Yes
354 (77.0%)
106 (23.0%)
< 0.001
No
1229 (92.5%)
99 (7.5%)
Diabetes mellitus
Yes
314 (91.3%)
30 (8.7%)
0.08
No
1269 (87.9%)
175 (12.1%)
Hypertension
Yes
677 (89.6%)
79 (10.4%)
0.25
No
906 (87.8%)
126 (12.2%)
Chronic kidney disease
Yes
354 (82.9%)
73 (17.1%)
<0.001
No
1223 (90.3%)
132 (9.7%)
Congestive heart failure
Yes
279 (82.8%)
58 (17.2%)
< 0.001
No
1304 (89.9%)
147 (10.1%)
Chronic obstructive pulmonary disease
Yes
96 (87.3%)
14 (12.7%)
0.67
No
1487 (88.6%)
191 (11.4%)
Bradycardia
Yes
853 (88.4%)
112 (11.6%)
0.84
No
730 (88.7%)
93 (11.3%)
Use of Remdesivir
Yes
789 (89.4%)
94 (10.6%)
0.28
No
748 (87.7%)
94 (12.3%)
Use of dexamethasone
Yes
1069 (87.6%)
151 (12.4%)
0.08
No
514 (90.5%)
54 (9.5%)
Table 5 Logistic regression on predictors of increased troponin elevation
B
SE
Wald
df
Sig
Exp (B)
95%CI for EXP (B)
Lower
Upper
Lactate dehydrogenase
0.000
0.000
8.091
1
0.004
1.000
1.000
1.001
Congestive heart failure
0.991
0.239
17.170
1
0.000
2.694
1.686
4.305
Intensive care unit
1.278
0.232
30.359
1
0.000
3.591
2.279
5.659
Constant
-3.154
0.194
264.436
1
0.000
0.043
Table 6 Cox regression analysis showing predictors of mortality in coronavirus disease 2019 patients
B
SE
Wald
df
Sig
Exp (B)
95%CI for Exp (B)
Lower
Upper
Age
0.022
0.004
26.460
1
0.000
1.022
1.014
1.031
Ventilator use
-0.378
0.157
5.830
1
0.016
0.685
0.504
0.931
Intensive care unit admission
1.624
0.164
97.657
1
0.000
5.074
3.677
7.003
Troponin
0.219
0.133
2.705
1
0.100
1.245
0.959
1.616
Citation: Umeh CA, Maoz H, Obi J, Dakoria R, Patel S, Maity G, Barve P. Remdesivir, dexamethasone and angiotensin-converting enzyme inhibitors use and mortality outcomes in COVID-19 patients with concomitant troponin elevation. World J Cardiol 2023; 15(9): 427-438